## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): McCormick\_et

Serial No.: 09/539,383

Filed: 3/31/2000

Title: Self Antigen Vaccines for Treating B-

Cell Lymphomas and Other Cancers

Attorney Docket No.: 42204

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Group Art Unit: 1642

Examiner: YAEN, Christopher H.

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Supplemental Information Disclosure Statement is submitted under 37 CFR 1.97(c) together with a \$180.00 fee under 37 CFR 1.17(p).

Applicant(s) submit herewith Form PTO 1449-Information Disclosure Citation together with copies, of patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

The relevance of the attached references is that this is the closest art of which Applicant is aware. Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

It is requested that the information disclosed herein be made of record in this application.

I hereby certify that this Correspondence is being deposited with the United States Postal service with sufficient postage for first class mail in an envelope address to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or the correspondence is being facsimile transmitted to the USPTO, on the date indicated below.

Date of Deposit:

Typed Name: Thomas Gallegos

Respectfully submitted,

Thomas Gallegos, Reg. No. 32,692 Attorney/Agent for Applicant(s)

Telephone No. (707) 469-2307

CILIENESS HULTERAS GCCCOCCO

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

1PE				Complete if Known				
FEE TRANSMITTA	Application Number			tion Num	nber	09/539,382		
	_	<b>9</b>	Filing D	ate		3/31/2000		
for FY 2004 JAN	112	ÜC5	First Named Inventor			McCormick, et al.		
\_			Examiner Name			YAEN, Christopher H.		
Effective 10/01/2003. Patent fees are subject to a first I revisit	m.	~~	Art Unit 1642			1642		
Applicant Claims small entity status. See 37	12/		A 44	Dl	1 1 1 -	42204	-	
TOTAL AMOUNT OF PAYMENT (\$) 180.00			Attome	y Docket	I NO.	42204		
METHOD OF DAVMENT A A MARKET	<del></del>					0111 471011 ( ) ( )		
METHOD OF PAYMENT (check all that apply)	<del></del>				E CAL	CULATION (continued)		
Check Credit card Money Other None		DDITIO Entity		EES				
X Deposit Account	Fee Code	Fee (\$)	Fee Code	Fee (\$)		Fee Description	Fee Paid	
Deposit Account 500933	1051	130	2051	65	Surcha	rge - late filing fee or oath		
Number Deposit Large Scale Biology Corporation	1052	50	2052	25	Surcha	rge – late provisional filing fee or		
Account Name	1002	-			cover	sheet	1 1	
The Director is authorized to: (check all that apply)	1053	130	1053	130	Non-E	nglish specification		
X Charge fee(s) indicated below X Credit any overpayments	1812	2,520	1812	2,520	For filir	ig a request for ex parte reexamination		
X Charge any additional fee(s) or any underpayment of fee(s)	1804	920*	1804	920*		sting publication of SIR prior to		
Charge fee(s) indicated below, except for the filing fee	1805	1,840*	1805	1,840*		sting publication of SIR after ner action		
to the above-identified deposit account.	ł						<b></b>	
FEE CALCULATION	1251	110	2251	55	Extens	ion for reply within first month		
1. BASIC FILING FEE	1252	430	2252	215		ion for reply within second month		
Large Entity Small Entity	1253	980	2253	490	Extens	ion for reply within third month		
Fee Fee Fee Fee Fee Description Code (\$) Code (\$) Fee Paid	1254	1,530	2254	765	Extens	ion for reply within fourth month		
1001 790 2001 395 Utility filing fee	1255	2,080	2255	1,040	Extens	ion for reply within fifth month		
1002 350 2002 175 Design filing fee	1401	340	2401	170		of Appeal		
1003 550 2003 275 Plant filing fee	1402	340	2402	170	-	a brief in support of an appeal		
1004 790 2004 395 Reissue filing fee	1403	300	2403	150	•	st for oral hearing		
1005 160 2005 80 Provisional filing fee	1451 1452	1,510 110	1451 2452	1,510 55		n to institute a public use proceeding n to revive – unavoidable		
SUBTOTAL (1) (\$)	1452	1,370	2452	685		n to revive – unavoidable		
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1501	1,370	2501	685		ssue fee (or reissue)		
Fee from	1502	490	2502	245	•	issue fee		
Extra Claims below Fee Paid  Total Claims -20**= X	1503	660	2503	330	•	ssue fee		
Independent 3**= X =	1460	130	1460	130		ns to the Commissioner		
Claims Use Multiple Dependent	1807	50	1807	50		ssing fee under 37 CFR 1.17(q)		
Large Entity   Small Entity	1806	180	1806	180		ssion of Information Disclosure Stmt	180.00	
Fee Fee Fee Fee Description	8021	40	8021	40	Recor	ding each patent assignment per		
Code (\$)   Code (\$)	1809	790	2809	395	Filing	ty (times number of properties) a submission after final rejection R 1.129(a))		
1201 88 2201 44 Independent claims in excess of 3	1810	790	2810	395	For ea	ch additional invention to be ned (37 CFR 1.129(b))		
1203 300 2203 150 Multiple dependent claim, if not paid	1801	790	2801	395	Reque	st for Continued Examination (RCE)		
1204 88 2204 44 **Reissue independent claims over original patent	1802	900	1802	900		st for expedited examination esign application		
1205 18 2205 9 **Reissue claims in excess of 20			'		V. a ut	and a shared on		

SUBMITTED BY			Complete (if applicable)		
Name (Print/Type)	Thomas Gallegos	Registration No. (Attorney/Agent)	32,692	Telephone	(707) 469-2307
Signature	They Calls			Date	70m 2005

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3)

(\$) 180.00

Other fee (specify)

and over original patent

SUBTOTAL (2)

\*\* or number previously paid, if greater; For Reissues, see above

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0331 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

42204

required, Under the Paperwork Reduction Act of 1995, no perso Ca respond to a collection of information unless it displays a valid OMB control number. Complete if Known Substitute for form 1449A/PTO JAN ! 1 2005 09/539,382 Application Number SUPPLEMENTA Filing Date 3/31/2000 INFORMATION DISCLOSURE First Named Inventor STATEMENT BY APPLICANT McCormick et al. Art Unit 1642 (Use as many sheets as necessary) **Examiner Name** Yaen, Christopher H.

Attorney Docket Number

	U.S. PATENT DOCUMENTS						
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant		
Initials*		MM-DD-YYYY	Applicant of Cited Document	Figures Appear			
		· · · · · · · · · · · · · · · · · · ·					

2

1

Sheet

	FOREIGN PATENT DOCUMENTS					
Examiner Cite	Foreign Patent Document  Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁰	
		WO 94/08008	4/14/1994	HAWKINS, et al.		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BENVENUTI and BURRONE, "Anti-idiotypic antibodies induced by genetic immunisation are directed exclusively against combined V <sub>L</sub> /V <sub>H</sub> determinants", <i>Gene Therapy</i> (2001) 8:1555-1561	
		DE GRUIJL and CURIEL, "Cancer vaccine stategies get bigger and better", <i>Nature Medicine</i> (1999) 5(10):1124-1125	
		DONNELLY, "Cancer vaccine targets leukemia", <i>Nature Medicine</i> (2003) 9(11):1354-1356	
		FIEDLER, et al., "Optimization of scFv antibody production in transgenic plants", Immunotechnology (1997) 3:205-216	
		HAKIM, et al., "A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines", <i>J. Immun.</i> (1996) 157(12):5503-5511	
		HENNECKE, et al., "Non-repetitive single-chain Fv linkers selected by selectively infective phage (SIP) technology", <i>Protein Engineering</i> (1998) 11(5):405-410	
		HSU, et al., "Tumor-Specific idiotype vaccines in the treatment of patients with B-cell lymphoma – long-term results of a clinical trial", <i>Blood</i> (1997) 89(9):3129-3135	

	······································		
		1 '	1
Examiner		Date	
Signature		Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.' Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons an respond to a collection of information unless it displays a valid OMB control number. Complete if Known Substitute for form 1449A/PTO JAN 1 1 2005 SUPPLEMENT 09/539,382 **Application Number** Filing Date 3/31/2000 INFORMATION DISCLOSURE First Named Inventor McCormick et al. STATEMENT BY APPLICANT Art Unit 1642 (Use as many sheets as necessary) **Examiner Name** Yaen, Christopher H. 2 Sheet 2 Attorney Docket Number 42204

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>			
		STEMMER, et al., "Selection of an active single chain Fv antibody from a protein linker library prepared by enzymatic inverse PCR", <i>Biotech</i> . (1993) 14(2):256-265				
		TAVLADORAKI, et al., "A single-chain antibody fragment is functionally expressed in the cytoplasm of both <i>Escherichia coli</i> and transgenic plants", <i>European J. Biochem.</i> (1999) 262(2):617-624				
		TURNER, et al., "Importance of the linker in expression of single-chain Fv antibody fragments: optimisation of peptide sequence using phage display technology", <i>J. Immun. Methods</i> (1997) 205(1):43-54				
***************************************						
Examiner Signature		Date Considered				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.